Sugi Predict

Sugi Predict / Compounds / SCHEMBL698930

SCHEMBL698930

SCHEMBL698930

O=C(O)CC[C@H](NS(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.86

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 17/20 0.86
▸ MMP8 P22894 7/20 0.86
▸ MMP13 P45452 1/20 0.86
▸ ADAMTS4 O75173 1/20 0.86
▸ MMP2 P08253 17/20 0.68
▸ MMP12 P39900 6/20 0.63
▸ MMP14 P50281 6/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716323 1.00 MMP9 (0.86) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL698929 1.00 MMP9 (0.86) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL14602275 0.92 MMP9 (1.00) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL14602271 0.92 MMP9 (1.00) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL31609930 0.92 MMP9 (1.00) MMP9MMP8MMP13ADAMTS4MMP2
Carglumic Acid SCHEMBL7824179 0.90 MMP9 (0.71) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL7906607 0.89 MMP9 (0.78) MMP9MMP8MMP13ADAMTS4MMP2
Toluene SCHEMBL7906483 0.89 MMP9 (0.78) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL6574668 0.88 MMP9 (0.86) MMP9MMP8MMP13ADAMTS4MMP2
SCHEMBL697840 0.86 MMP9 (0.74) MMP9MMP8MMP13ADAMTS4MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106432188-A Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide 青岛辰达生物科技有限公司 2017-02-22 — — CN claimed
US-8592625-B2 Process for resolving S-3-(aminomethyl)-5-methylhexanoic acid Zheinjiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2013-11-26 — — US claimed
CN-102274130-A Application of n- benzene sulfonyl-l-glutamic acid or saline thereof — 2011-12-14 — — CN claimed
US-20110098502-A1 NEW PROCESS FOR RESOLVING S-3- (AMINOMETHYL)-5-METHYLHEXANOIC ACID Zheijiang Jiuzhou Pharmaceutical Co., Ltd. 2011-04-28 — — US claimed
EP-1457487-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES Toray Fine Chemicals Co., Ltd. (JP) 2004-09-15 — — EP claimed
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) 2004-09-02 — — US claimed
JP-6107604-A — — None — — JP disclosed
US-12624109-B2 αv-integrin targeted small molecule drug conjugates TARGETTHERA LLC (US) 2026-05-12 — — US disclosed
EP-4704909-A2 ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES Targetthera LLC (US) 2026-03-11 — — EP disclosed
US-20240376212-A1 ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES TARGETTHERA LLC 2024-11-14 — — US disclosed
WO-2024226357-A2 ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES TARGETTHERA LLC (US) 2024-10-31 — — WO disclosed
EP-1688126-B1 GLYCYLGLYCINE AS PARAKERATOSIS INHIBITOR SHISEIDO CO LTD (JP) 2017-08-23 — — EP disclosed
CN-106432188-A Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide 青岛辰达生物科技有限公司 2017-02-22 — — CN disclosed
US-5952503-A Method for producing optically-active 2-piperazinecarboxylic acid derivatives TORAY INDUSTRIES, INC. (JP) 1999-09-14 — — US disclosed
EP-0906906-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2-PIPERAZINECARBOXYLIC ACID DERIVATIVES TORAY INDUSTRIES, INC. (JP) 1999-04-07 — — EP disclosed
JP-H06107604-A PRODUCTION OF OPTICALLY ACTIVE 1-@(3754/24)4-HALOGENOPHENYL) ETHYLAMINE TORAY IND INC 1994-04-19 — — JP disclosed
EP-0142191-B1 A PROCESS FOR ISOLATING LEVAMISOLE FROM TETRAMISOLE JANSSEN PHARMACEUTICA N.V. (BE) 1990-03-14 — — EP disclosed
US-4672126-A ADDING L-N-((4-METHOXYPHENYL)SULFONYL)-GLUTAMIC ACID; PRECIPITATION JANSSEN PHARMACEUTICA, N.V. (BE) 1987-06-09 — — US disclosed
EP-0142191-A2 A process for isolating levamisole from tetramisole JANSSEN PHARMACEUTICA N.V. (BE) 1985-05-22 — — EP disclosed
EP-0120438-A1 Optical antipodes of 8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinoline, process for its preparation and pharmaceutical compositions having an anti-depressive action containing it HOECHST AKTIENGESELLSCHAFT (DE) 1984-10-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TYR, DDC, TARBP1 MMP9 1373/4885MMP8 2925/4885MMP13 1152/4885
US-12624109-B2 αv-integrin targeted small molecule drug conjugates ITGA1, ITGB1, ITGA2 MMP9 1841/4885MMP8 1912/4885MMP13 2902/4885
US-20240376212-A1 ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES ITGA1, ITGAL, ITGAV MMP9 2266/4885MMP8 2976/4885MMP13 3652/4885
US-20110098502-A1 NEW PROCESS FOR RESOLVING S-3- (AMINOMETHYL)-5-METHYLHEXANOIC ACID GABRD, GRM2, GRM3 MMP9 1146/4885MMP8 4345/4885MMP13 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.